Iterum Therapeutics PLC (ITRM)

Last Price: 0.66 (2020-09-18)

Company Description

Iterum Therapeutics plc is a clinical-stage pharmaceutical company. It develops and markets therapies to address unmet medical needs, as well as provides anti-infectives to treat multi-drug resistant pathogens. The company's product pipeline consists of uncomplicated urinary tract infections, complicated urinary tract infections and complicated intra abdominal infections. Iterum Therapeutics plc is based in Dublin, Ireland.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $0.04M
Net Income (Most Recent Fiscal Year) $-103.13M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) --
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -277529.72%
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -880.10%
Return on Assets (Trailing 12 Months) -214.52%
Current Ratio (Most Recent Fiscal Quarter) 0.45
Quick Ratio (Most Recent Fiscal Quarter) 0.45
Debt to Common Equity (Most Recent Fiscal Quarter) --
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $-1.88
Earnings per Share (Most Recent Fiscal Quarter) $-0.80
Earnings per Share (Most Recent Fiscal Year) $-7.10
Diluted Earnings per Share (Trailing 12 Months) $-5.62
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 21.24M
Free Float 13.15M
Market Capitalization $14.34M
Average Volume (Last 20 Days) 0.17M
Beta (Past 60 Months) 0.95
Percentage Held By Insiders (Latest Annual Proxy Report) 38.10%
Percentage Held By Institutions (Latest 13F Reports) 29.01%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%